Tandem Diabetes Care (TNDM) Capital Expenditures Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 10.17% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 1.81% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 2.15% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 0.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.35% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 8.08% |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | 15.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.47% |
| Dec 31, 2025 | 50.33% |
| Sep 30, 2025 | -26.36% |
| Jun 30, 2025 | -29.19% |
| Mar 31, 2025 | 3.91% |
| Dec 31, 2024 | -47.09% |
| Sep 30, 2024 | 119.85% |
| Jun 30, 2024 | 150.39% |
| Mar 31, 2024 | 68.96% |
| Dec 31, 2023 | -226.52% |
| Sep 30, 2023 | 103.48% |
| Jun 30, 2023 | 60.00% |
| Mar 31, 2023 | -15.58% |
| Dec 31, 2022 | -30.90% |
| Sep 30, 2022 | 82.78% |
| Jun 30, 2022 | 131.24% |
| Mar 31, 2022 | 23.36% |
| Dec 31, 2021 | 65.32% |
| Sep 30, 2021 | 152.43% |
| Jun 30, 2021 | -55.72% |
| Mar 31, 2021 | 62.08% |
| Dec 31, 2020 | -27.95% |
| Sep 30, 2020 | 29.28% |
| Jun 30, 2020 | -52.02% |
| Mar 31, 2020 | 209.15% |
| Dec 31, 2019 | 83.89% |
| Sep 30, 2019 | 1.63% |
| Jun 30, 2019 | -32.46% |
| Mar 31, 2019 | 47.25% |
| Dec 31, 2018 | 20.60% |
| Sep 30, 2018 | -26.28% |
| Jun 30, 2018 | -28.81% |
| Mar 31, 2018 | -28.75% |
| Dec 31, 2017 | 96.34% |
| Sep 30, 2017 | -82.78% |
| Jun 30, 2017 | 52.92% |
| Mar 31, 2017 | -47.91% |
| Dec 31, 2016 | 22.84% |
| Sep 30, 2016 | 24.29% |
| Jun 30, 2016 | 91.33% |
| Mar 31, 2016 | -21.20% |